Δευτέρα, 9 Μαρτίου 2015

Rett Syndrome Research Trust Awards $1.3 Million for Low-Dose Ketamine Phase 2 Trial

Rett Syndrome Research Trust Awards $1.3 Million for Low-Dose Ketamine Phase 2 Trial



"Previous studies by Katz and colleagues showed low-dose ketamine to reverse deficits in brain activity in mouse models of Rett syndrome, while also significantly improving neurologic function, including breathing."


Δεν υπάρχουν σχόλια :

Δημοσίευση σχολίου